Biotech CSL NPAT rises 11%

14/08/2019 10:50:00

This video is not supported on your device. Click here for the original version.
Biotech CSL (ASX:CSL) report their Net Profit After Tax US$1.9 billion up 11 per cent on the prior corresponding period US$1.7 billion.

The company has seen increased demand for its blood-based therapies - immunoglobulin and albumin therapies.

Seasonal flu vaccine sales also increased in demand.

Total revenue $8.5 billion from last year's $7.9 billion.

Final dividend was a rise on last year's 93 US cents to US$1:00.

Shares in CSL (ASX:CSL) are trading 6.8 per cent higher at $234.42